K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, Christos S., Khambata-Ford, Shirin, Jonker, Derek J., O'Callaghan, Chris J., Tu, Dongsheng, Tebbutt, Niall C., Simes, R. John, Chalchal, Haji +8 more·2008·New England Journal of Medicine
DOI 10.1056/nejmoa0804385

Cited by (138)

Items 101–138 of 138

  1. In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer
    Veluchamy, John P., Lopez-Lastra, Silvia, Spanholtz, Jan, Bohme, Fenna, Kok, Nina, Heideman, Daniëlle A. M., Verheul, Henk M. W., Di Santo, James P., de Gruijl, Tanja D., van der Vliet, Hans J. · 2017 · Frontiers in Immunology
  2. Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
    Zocche, David M., Ramirez, Carolina, Fontao, Fernando M., Costa, Lucas D., Redal, María A. · 2015 · Frontiers in Genetics
  3. KRAS mutational status in Japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study
    Watanabe, Toshiaki, Yoshino, Takayuki, Uetake, Hiroyuki, Yamazaki, Kentaro, Ishiguro, Megumi, Kurokawa, Tatsuo, Saijo, Nagahiro, Ohashi, Yasuo, Sugihara, Kenichi · 2013 · Japanese Journal of Clinical Oncology
  4. Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
    Yu, Irene S., Cheung, Winson Y. · 2018 · Canadian Journal of Gastroenterology and Hepatology
  5. The role of wild-type RAS in oncogenic RAS transformation
    Sheffels, Erin, Kortum, Robert L. · 2021 · Genes
  6. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Niciu, Mark J., Mathews, Daniel C., Nugent, Allison C., Ionescu, Dawn F., Furey, Maura L., Richards, Erica M., Machado-Vieira, Rodrigo, Zarate, Carlos A. · 2014 · Depression and Anxiety
  7. Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
    Bertotti, Andrea, Sassi, Francesco · 2015 · Clinical Cancer Research
  8. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
    Johnson, Radia M., Qu, Xueping, Lin, Chu-Fang, Huw, Ling-Yuh, Venkatanarayan, Avinashnarayan, Sokol, Ethan, Ou, Fang-Shu, Ihuegbu, Nnamdi, Zill, Oliver A., Kabbarah, Omar et al. · 2022 · Nature Communications
  9. Broad Detection of Alterations Predicted to Confer Lack of Benefit from EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
    Rankin, Andrew, Klempner, Samuel J., Erlich, Rachel, Sun, James X., Grothey, Axel, Fakih, Marwan, George, Thomas J., Lee, Jeeyun, Ross, Jeffrey S., Stephens, Philip J. et al. · 2016 · The Oncologist
  10. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
    Price, T J, Bruhn, M A, Lee, C K, Hardingham, J E, Townsend, A R, Mann, K P, Simes, J, Weickhardt, A, Wrin, J W, Wilson, K et al. · 2015 · British Journal of Cancer
  11. Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer
    Loree, Jonathan M., Wang, Yucai, Syed, Muddassir A., Sorokin, Alexey V., Coker, Oluwadara, Xiu, Joanne, Weinberg, Benjamin A., Vanderwalde, Ari M., Tesfaye, Anteneh, Raymond, Victoria M. et al. · 2021 · Clinical Cancer Research
  12. The evolution within us
    Cobey, Sarah, Wilson, Patrick, Matsen, Frederick A. · 2015 · Philosophical Transactions of the Royal Society B: Biological Sciences
  13. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
    Tria, Simon Manuel, Burge, Matthew E., Whitehall, Vicki L. J. · 2023 · Cancers
  14. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
    Bekaii-Saab, Tanios S, Lach, Krzysztof, Hsu, Ling-I, Siadak, Muriel, Stecher, Mike, Ward, James, Beckerman, Rachel, Strickler, John H · 2023 · The Oncologist
  15. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade
    Kasper, S, Breitenbuecher, F, Reis, H, Brandau, S, Worm, K, Köhler, J, Paul, A, Trarbach, T, Schmid, K W, Schuler, M · 2013 · Oncogene
  16. Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer
    Huang, Fei, Xu, Li-an, Khambata-Ford, Shirin · 2012 · Clinical Cancer Research
  17. MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling
    Han, Ying, Peng, Yinghui, Fu, Yaojie, Cai, Changjing, Guo, Cao, Liu, Shanshan, Li, Yiyi, Chen, Yihong, Shen, Edward, Long, Kexin et al. · 2020 · Advanced Science
  18. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
    Pandey, Divya, Chauhan, Subhash C., Kashyap, Vivek K., Roy, Kuldeep K. · 2024 · European Journal of Medicinal Chemistry
  19. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
    Knickelbein, Kyle, Tong, Jingshan, Chen, Dongshi, Wang, Yi-Jun, Misale, Sandra, Bardelli, Alberto, Yu, Jian, Zhang, Lin · 2018 · Oncogene
  20. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
    Elez, E, Hendlisz, A, Delaunoit, T, Sastre, J, Cervantes, A, Varea, R, Chao, G, Wallin, J, Tabernero, J · 2016 · British Journal of Cancer
  21. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
    Loupakis, Fotios, Cremolini, Chiara, Fioravanti, Anna, Orlandi, Paola, Salvatore, Lisa, Masi, Gianluca, Schirripa, Marta, Di Desidero, Teresa, Antoniotti, Carlotta, Canu, Bastianina et al. · 2014 · Targeted Oncology
  22. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma
    Krol, L.C., ’t Hart, N.A., Methorst, N., Knol, A.J., Prinsen, C., Boers, J.E. · 2012 · European Journal of Cancer
  23. EGFR-specific tyrosine kinase inhibitor modifies NK cell-mediated antitumoral activity against ovarian cancer cells
    Mallmann-Gottschalk, Nina, Sax, Yvonne, Kimmig, Rainer, Lang, Stephan, Brandau, Sven · 2019 · International Journal of Molecular Sciences
  24. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
    Tsigelny, Igor F., Wheler, Jennifer J., Greenberg, Jerry P., Kouznetsova, Valentina L., Stewart, David J., Bazhenova, Lyudmila, Kurzrock, Razelle · 2015 · Oncotarget
  25. Neratinib-Plus-Cetuximab in Quadruple-WT ( <i>KRAS, NRAS, BRAF, PIK3CA</i> ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
    Jacobs, Samuel A., Lee, James J., George, Thomas J., Wade, James L., Stella, Philip J., Wang, Ding, Sama, Ashwin R., Piette, Fanny, Pogue-Geile, Katherine L., Kim, Rim S. et al. · 2021 · Clinical Cancer Research
  26. The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab
    Strimpakos, Alexios, Pentheroudakis, George, Kotoula, Vassiliki, De Roock, Wendy, Kouvatseas, George, Papakostas, Pavlos, Makatsoris, Thomas, Papamichael, Demetris, Andreadou, Anna, Sgouros, Joseph et al. · 2013 · Clinical Colorectal Cancer
  27. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
    Augustine, T A, Baig, M, Sood, A, Budagov, T, Atzmon, G, Mariadason, J M, Aparo, S, Maitra, R, Goel, S · 2015 · British Journal of Cancer
  28. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer
    Hanada, Keita, Kawada, Kenji, Nishikawa, Gen, Toda, Kosuke, Maekawa, Hisatsugu, Nishikawa, Yasuyo, Masui, Hideyuki, Hirata, Wataru, Okamoto, Michio, Kiyasu, Yoshiyuki et al. · 2021 · Cancer Letters
  29. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
    Ye, Hua, Liu, Yi, Wu, Kefeng, Luo, Hui, Cui, Liao · 2020 · Cell Communication and Signaling
  30. Randomised Phase II Study of Panitumumab plus Irinotecan versus Cetuximab plus Irinotecan in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G)
    Sakai, Daisuke, Taniguchi, Hiroya, Sugimoto, Naotoshi, Tamura, Takao, Nishina, Tomohiro, Hara, Hiroki, Esaki, Taito, Denda, Tadamichi, Sakamoto, Takeshi, Okuda, Hiroyuki et al. · 2020 · European Journal of Cancer
  31. Panitumumab interaction with<scp>TAS</scp>‐102 leads to combinational anticancer effects via blocking of<scp>EGFR</scp>‐mediated tumor response to trifluridine
    Baba, Yuji, Tamura, Toshiya, Satoh, Yoshihiko, Gotou, Masamitsu, Sawada, Hiroshi, Ebara, Shunsuke, Shibuya, Kazunori, Soeda, Jumpei, Nakamura, Kazuhide · 2017 · Molecular Oncology
  32. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS<sup>G12D</sup>Inhibitor, in Colorectal Cancer Treatment
    KATAOKA, MASAHIRO, KITAZAWA, MASATO, NAKAMURA, SATOSHI, KOYAMA, MAKOTO, YAMAMOTO, YUTA, MIYAZAKI, SATORU, HONDO, NAO, TANAKA, HIROKAZU, SOEJIMA, YUJI · 2023 · Anticancer Research
  33. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
    Lièvre, Astrid, Ouine, Bérèngere, Canet, Jim, Cartier, Aurélie, Amar, Yael, Cacheux, Wulfran, Mariani, Odette, Guimbaud, Rosine, Selves, Janick, Lecomte, Thierry et al. · 2017 · British Journal of Cancer
  34. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient with Treatment Refractory Metastatic Colorectal Cancer
    Jia, Jingquan, Morse, Michael A., Nagy, Rebecca J., Lanman, Richard B., Strickler, John H. · 2018 · Frontiers in Oncology
  35. A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells
    Ressa, Anna, Bosdriesz, Evert, de Ligt, Joep, Mainardi, Sara, Maddalo, Gianluca, Prahallad, Anirudh, Jager, Myrthe, de la Fonteijne, Lisanne, Fitzpatrick, Martin, Groten, Stijn et al. · 2018 · Molecular &amp; Cellular Proteomics
  36. Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: Post hoc analysis of the phase III SUNLIGHT trial
    Tabernero, J., Taieb, J., Fakih, M., Prager, G.W., Van Cutsem, E., Ciardiello, F., Mayer, R.J., Amellal, N., Skanji, D., Calleja, E. et al. · 2024 · ESMO Open
  37. RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches
    Sütcüoğlu, Osman, Yıldırım, Hasan Çağrı, Almuradova, Elvina, Günenç, Damla, Yalçın, Şuayib · 2025 · Medicina
  38. Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V
    Sagawa, Tamotsu, Hirakawa, Masahiro, Nagashima, Hiroyuki, Fujikawa, Koshi · 2026 · Journal of Gastrointestinal Cancer